Patients are searching for this trial right now

This page is already ranking on Google. Activate it to start receiving pre-qualified patient leads directly in your inbox.

14-day free trial · $44/mo after · Cancel anytime · Money-back guarantee

NCT06098612 · Massachusetts General Hospital

PET Imaging Evaluation of [11C]SY08

What this study is about

The overall goal of the proposed research is to evaluate the use of \[11C\]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls.

View original scientific description

The overall goal of the proposed research is to evaluate the use of \[11C\]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls. The purpose of this study is to evaluate the use of \[11C\]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls. The specific aims of the current study are: 1. To determine brain uptake, distribution, and kinetics of \[11C\]SY08 in healthy individuals. 2. To determine brain uptake, distribution, and kinetics of \[11C\]SY08 in patients with alpha synuclein aggregates in the brain, including PD, DLB and MSA. 3. To determine human dosimetry of \[11C\]SY08 in healthy individuals An intravenous bolus injection of \[11C\]SY08 will be administered per subject for brain PET imaging.

Interventions

DRUG

C11-SY08

a PET imaging agent

Primary outcome measures

brain uptake evaluation

Time frame: up tp 120 minutes

The investigators will use SUV or SUV to evaluate brain uptake

Who can participate

This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.

Inclusion criteria

  • General Inclusion criteria, all subjects must:
  • Be able to provide written informed consent or assent
  • Be able to read, speak and understand English (The investigators do not have the resources necessary to properly study non-English speaking patients in this study, given that translation and validation of the assessment tools would be necessary)
  • Be willing and able to participate in one PET/MRI scanning session Additional Inclusion criteria for PD patients, subjects must:
  • Have an existing diagnosis of idiopathic PD, using consensus criteria
  • Stable medications for at least 30 days
  • Hoehn and Yahr stage I-IV
  • A study partner who can answer questions pertaining to daily functioning Additional Inclusion criteria for MSA patients, subjects must:
  • Have an existing diagnosis of MSA, using consensus criteria
  • Stable medications for at least 30 days
  • MSAp or MSAc
  • A study partner who can answer questions pertaining to daily functioning Additional Inclusion criteria for DLB patients, subjects must:
  • Have an existing diagnosis of probable DLB, using consensus criteria
  • Stable medications for at least 30 days
  • Clinical Dementia Rating Scale (CDR) \< 0.5
  • A study partner who can answer questions pertaining to daily functioning

Exclusion criteria

  • General Exclusion Criteria (All Subjects)
  • History of vascular risk factors (e.g. hypertension, hyperlipidemia), if not well-controlled
  • Major psychiatric disease (e.g.schizophrenia)
  • History of stroke
  • Focal brain lesions on MRI scans
  • History of other major illnesses including, but not limited to, major kidney or liver problems or significant neurological illness
  • Recent surgery that is deemed major by our reviewing physician or nurse practitioner within the past 6 months
  • History of head trauma (as defined as having any insults to the brain that may have resulted from an external mechanical force, such as rapid acceleration or deceleration, impact, blast waves, or penetration by a projectile)
  • Impaired elimination (as defined as having problems with urination) unless being managed
  • Past or present diagnosis of bipolar disorder or other Axis I diagnosis, (treated depression is allowed)
  • Any present substance abuse including drug/alcohol abuse
  • Inability to lie flat on camera bed for up to 90 min
  • Pregnancy or breastfeeding
  • Metallic foreign bodies that would be affected by the MRI magnet, or fear of enclosed spaces likely to make the subject unable to undergo an MRI scan
  • Recent exposure to radiation (i.e., PET from other research) that, when combined with this study, would be above the allowable limits (50 milliSieverts) General MR and PET safety exclusion criteria listed below
  • Ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, metallic tattoos anywhere on the body, tattoos near the eye, steel implants, ferromagnetic objects such as jewelry or metal clips in clothing
  • Electrical implants such as cardiac pacemakers or perfusion pumps
  • Pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest
  • Is unable to lie comfortably on a bed inside a PET camera with their head in the field of view for 60 to 90 minutes as assessed by physical examination and medical history (e.g. back pain, arthritis)
  • Pregnancy: A negative serum pregnancy test is required on the day of the PET procedure in women of child bearing potential
  • Body weight of \> 300 lbs (weight limit of the MRI table)
  • Breast feeding mothers Exclusion Criteria for Subjects Undergoing Blood Draws Through an Arterial Line During PET Scan
  • An abnormal result on the modified Allen's test on both hands
  • Raynaud syndrome
  • Bleeding disorder
  • Use of anticoagulants such as Coumadin, Plavix or Lovenox
  • An allergy to Lidocaine

Where

  • Charlestown, Massachusetts

Related conditions & keywords

Parkinson's DiseaseMultiple System AtrophyDementia With Lewy BodiesHealthy Controls

Frequently asked questions

What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Data: ClinicalTrials.gov · synced Dec 24, 2025 · Source of record for eligibility and locations

📊
1 of 40 participants interested
3% interest

See if this study fits

A short prescreen based on this study's listed criteria. A coordinator confirms eligibility — this is not a medical assessment.

Preparing your pre-screening questions…

Study locations

Choose your preferred location, or select flexible during enrollment.

RECRUITING

Charlestown

Massachusetts

Location available

Express your interest

Share your contact details and a study coordinator can follow up about screening.

Secure & Confidential

Your information is protected and will only be shared with the research team.

What participation can include

  • Study-related care provided by the research team
  • Close monitoring by medical professionals
  • Possible compensation for time and travel*
  • The option to withdraw at any time
  • Contributing to medical research that may help future patients

*Compensation varies by study. Confirm details with coordinator.

Typical next steps

  1. 1.Submit this form
  2. 2.Phone screening
  3. 3.In-person assessment if eligible
  4. 4.Begin participation

Find More Parkinsons Disease Trials by City

Browse all parkinsons disease clinical trials in these cities — not just this study.

Looking for Parkinson's Disease Treatment in Charlestown?

Join others in Massachusetts exploring innovative treatment options through clinical research

Parkinson's Disease Treatment Options in Charlestown, Massachusetts

If you're searching for Parkinson's Disease treatment in Charlestown, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Charlestown and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Parkinson's Disease. All study-related care is provided at no cost to participants.

Local Sites
1 locations in Massachusetts
Now Enrolling
Up to 40 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Parkinson's Disease?

Potential Benefits

  • Access to new treatment approaches before public availability
  • Close monitoring by experienced medical professionals
  • Study-related care provided at no cost
  • Contribute to medical research for Parkinson's Disease

What to Expect

  • Initial screening to determine eligibility
  • Regular check-ups and monitoring visits
  • Possible compensation for time and travel
  • You can withdraw at any time

Frequently Asked Questions About This Parkinson's Disease Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT06098612. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.